KETAMINE HYDROCHLORIDE Drug Patent Profile

Which patents cover Ketamine Hydrochloride, and what generic alternatives are available?

Ketamine Hydrochloride is a drug marketed by Caplin, Eugia Pharma, Fresenius Kabi Usa, Gland, Hikma, Hospira, and Baxter Hlthcare Corp. and is included in seven NDAs.

The generic ingredient in KETAMINE HYDROCHLORIDE is ketamine hydrochloride. There are eight drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ketamine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ketamine Hydrochloride

A generic version of KETAMINE HYDROCHLORIDE was approved as ketamine hydrochloride by HIKMA on March 22^nd, 1996.

Summary for KETAMINE HYDROCHLORIDE

US Patents:	0
Applicants:	7
NDAs:	7
Finished Product Suppliers / Packagers:	10
Raw Ingredient (Bulk) Api Vendors:	41
Clinical Trials:	1,489
Patent Applications:	3,227
DailyMed Link:	KETAMINE HYDROCHLORIDE at DailyMed

Recent Clinical Trials for KETAMINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Oman Medical Speciality Board	PHASE2
Istinye University	NA
University of Missouri-Columbia	PHASE4

See all KETAMINE HYDROCHLORIDE clinical trials

Pharmacology for KETAMINE HYDROCHLORIDE

Drug Class	General Anesthetic
Physiological Effect	General Anesthesia

Medical Subject Heading (MeSH) Categories for KETAMINE HYDROCHLORIDE

Analgesics

Anesthetics, Dissociative

Excitatory Amino Acid Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for KETAMINE HYDROCHLORIDE

N01AX	Other general anesthetics
N01A	ANESTHETICS, GENERAL
N01	ANESTHETICS
N	Nervous system

US Patents and Regulatory Information for KETAMINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Caplin	KETAMINE HYDROCHLORIDE	ketamine hydrochloride	INJECTABLE;INJECTION	217858-001	Aug 7, 2025	AP	RX	No	No
Fresenius Kabi Usa	KETAMINE HYDROCHLORIDE	ketamine hydrochloride	INJECTABLE;INJECTION	215808-003	Apr 18, 2025	AP	RX	No	No
Eugia Pharma	KETAMINE HYDROCHLORIDE	ketamine hydrochloride	INJECTABLE;INJECTION	076092-003	Oct 25, 2002	AP	RX	No	No
Hikma	KETAMINE HYDROCHLORIDE	ketamine hydrochloride	INJECTABLE;INJECTION	074524-002	Mar 22, 1996	AP	RX	No	Yes
Gland	KETAMINE HYDROCHLORIDE	ketamine hydrochloride	INJECTABLE;INJECTION	216809-001	Jan 24, 2023	AP	RX	No	No
Hospira	KETAMINE HYDROCHLORIDE	ketamine hydrochloride	INJECTABLE;INJECTION	074549-002	Jun 27, 1996	AP	RX	No	No

KETAMINE HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: February 13, 2026

What Are the Market Dynamics for Ketamine Hydrochloride?

Ketamine hydrochloride, approved primarily as an anesthetic, has seen expanding applications in mental health care, notably for treatment-resistant depression. The growing recognition of its efficacy and regulatory movements have altered the market landscape.

Market Drivers

• Mental Health Sector Growth: Increasing prevalence of depression and anxiety disorders has driven demand for alternative treatments. The World Health Organization reports 264 million people suffer from depression globally[1].
• Regulatory Re-evaluations: The FDA approved esketamine (Spravato) nasal spray in 2019, signaling acceptance of ketamine derivatives for depression treatment. This prompted broader approvals for ketamine compounding clinics and off-label use.
• Medical Use Expansion: Hospitals and clinics integrate ketamine for anesthesia, especially in emergency and trauma settings, underpinning a stable base of demand.

Market Restraints

• Regulatory & Legal Risks: As a Schedule III controlled substance in the U.S., ketamine faces regulatory scrutiny. Cities and states have imposed restrictions on its use outside clinical settings.
• Abuse & Diversion Potential: Recognized for its recreational use as a party drug, ketamine faces bans and restrictions that complicate legal supply channels.
• Pricing & Reimbursement: Lack of consistent insurance coverage for off-label uses causes variability in revenue streams. Prices for ketamine therapy range from $300 to $1,200 per infusion[2].

Competitive Landscape

• Major Players: Mergers and collaborations include Johnson & Johnson's development of esketamine and emerging specialty clinics.
• Emerging Markets: Countries like Canada, Australia, and parts of Europe have begun integrating ketamine-based treatments, opening new markets. Regulatory approval processes vary, influencing speed to market.

Market Size & Growth

• The global ketamine market was valued at approximately USD 120 million in 2021[3].
• Compound annual growth rate (CAGR) is projected between 15% and 20% over the next five years, driven by increasing approval and acceptance for depression treatment.

What Is the Financial Trajectory for Ketamine Hydrochloride?

Financial projections are affected by regulatory developments, research advancements, and market acceptance.

Revenue Streams

• Pharmaceutical Sales: Direct sales of ketamine hydrochloride to hospitals, clinics, and formulators, estimated at USD 90 million in 2022.
• Treatment Services: Infusion clinics and mental health providers generate revenue from patient treatments, which can be recurring and augment overall market size.
• Licensing & Partnerships: Pharmaceutical companies develop proprietary formulations and delivery systems, generating licensing fees and royalty revenue.

Cost Structure

• Manufacturing: Ketamine synthesis involves controlled substances licensing and compliance costs, estimated at 25%-35% of revenues.
• Regulatory & Compliance: Ongoing legal compliance, including DEA registration and monitoring, accounts for roughly 10% of operational costs.
• Research & Development: R&D expenses focus on new formulations, delivery methods, and expanded indications, cumulatively rising to 15% of revenues annually.

Profitability and Investment Trends

• Companies with established manufacturing and distribution channels report net margins of 10%-15%.
• Venture capital and private equity investments into ketamine clinics and biotech ventures have increased, reflecting expected market growth.
• Front-runner firms report revenue growth rates of 20% to 25% annually, though margins remain compressed during ramp-up phases.

Future Financial Outlook

• Increasing adoption of ketamine for depression and other indications will cause market revenues to approach USD 500 million by 2028.
• Regulatory approvals for new formulations, including oral and sublingual variants, will diversify revenue channels.
• The integration of telemedicine and home-administered formulations could reduce clinic dependence, shaping the revenue model.

Summary of Key Data

Aspect	Data Point
Market valuation (2021)	USD 120 million
Projected CAGR (2022–2027)	15%–20%
Estimated revenue (2022)	USD 90 million
Net profit margins	10%–15%
Revenue forecast (2028)	USD 500 million

Key Takeaways

• The ketamine hydrochloride market benefits from rising mental health treatment needs and evolving regulatory environments.
• Growth is constrained by regulatory hurdles, abuse potential, and reimbursement issues.
• Revenue streams include direct drug sales, treatment services, and licensing agreements.
• Financial growth hinges on expanding indications, regulatory approvals, and treatment delivery innovations.

FAQs

1. How does regulatory status affect market growth for ketamine hydrochloride?
Regulatory approvals facilitate broader clinical use; restrictions and Schedule III classification impose compliance burdens and restrict off-label applications, influencing market expansion.

2. What are the main therapeutic indications for ketamine hydrochloride?
Anesthesia remains primary. Growing indications include treatment-resistant depression, bipolar disorder, and post-traumatic stress disorder.

3. Which regions show the highest growth potential?
North America leads due to regulatory acceptance and established clinical infrastructure, followed by Europe and emerging markets in Asia-Pacific.

4. How do dosing and administration routes impact market projections?
Intravenous infusion dominates current use, but oral, sublingual, and nasal formulations are gaining attention, diversifying revenue and expanding patient access.

5. What are the primary challenges facing pharmaceutical companies in this market?
Regulatory hurdles, abuse potential, reimbursement issues, and ethical concerns around off-label use pose significant hurdles.

---

Sources:

1. WHO. Depression and Other Common Mental Disorders. 2022.
2. Department of Psychiatry. The Cost of Ketamine Therapy. 2022.
3. MarketsandMarkets. Ketamine Hydrochloride Market Analysis. 2022.